Open an account

Onkure Therapeutics

OKUR · NASDAQ

$2.36+$0.11 (+4.89%)TodayMarket closed ·
Prev close $2.25

OKUR analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy2
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 7 analysts

Average $16.12 (+582.9% upside)

Low
$11.11
Now
$2.36
High
$22.05

Upgrades and downgrades

The latest rating actions, newest first

OKUR analyst upgrades, downgrades and rating actions
FirmDateActionRating
OppenheimerAug 14, 2026MaintainsOutperform
HC Wainwright & Co.Jul 20, 2026MaintainsBuy
HC Wainwright & Co.Mar 16, 2026MaintainsBuy

The case for and against

Updated Oct 18, 2026

Bull case

OnKure Therapeutics is well positioned by a differentiated structure-based platform that is advancing OKI-345 and OKI-355 as selective inhibitors of mutant PI3Kα while sparing wild-type PI3Kα, a design that could improve efficacy and tolerability versus older targeted agents. The company’s recent quarterly update and KOL event reinforced the scientific rationale for broader hotspot coverage, deeper target inhibition, and a wider therapeutic index, while preclinical data showed strong cellular selectivity across PI3KαH1047R, PI3KαE545K, and PI3KαE542K. Financially, OnKure ended 2Q with $176M in cash, which should fund operations into 2029, supporting continued development through anticipated IND submissions in 1H27 and expanding its clinical and commercial opportunity in PI3Kα-driven cancers.

Bear case

OnKure Therapeutics is a clinical-stage biopharmaceutical company with no operating revenue shown in the provided data, and the “Collaboration revenue, related party” line reported as a dash underscores the lack of meaningful commercial traction. Its business remains concentrated in a single clinical research segment and heavily dependent on unproven precision-medicine programs, especially the PI3Kα-focused OKI-219, which increases binary clinical and development risk. With no evidence here of diversified revenue streams, approved products, or scale, the fundamental story appears reliant on future trial success rather than current financial performance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.